23andme semaglutide As a medical school professor, I get asked why GLP-1 drugs work miracles for some and barely budge for others. A new Nature paper from gives part of the answer: your 23andMe's New GLP-1 Service: Exploring

If approved, we believe pemvidutide could offer an important option for obesity patients, including those with risk factors for cardiovascular disease. However, tolerability issues remain, as the trial led to one participant experiencing vomiting, and 4.1% of the patients in the drug cohort discontinuing treatment in the first 16 weeks, when compared to 2.1% in the placebo group

food labels to shed Frankenstein ingredients image: Reuters exclusive As AI grows more powerful, a U.S.-China feud threatens safety efforts Teslas once-bullish tone on robotaxis shifts Health Medical paper argues for dialogue on death by organ donation, but experts raise moral concerns Toilet humor over diarrhea-induced weight loss shows fat phobia is alive and well Research links blood test results to early Alzheimers Entertainment The Odyssey earns US$87M in its second weekend, Christopher Nolans best second weekend yet Lucas Museum to display unseen Star Wars pieces, curator says Embrace difference, says 4-foot-6 B.C

2008 Jan;18(9):739-43

Glucagon-like peptide-1 reduces the pulsatile component of testosterone secretion in healthy males